-
公开(公告)号：US11697688B2
公开(公告)日：2023-07-11
申请号：US16979935
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , James Geoghegan , Bianka Prinz , Sergio Quezada
CPC classification number: C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/55 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US20210054084A1
公开(公告)日：2021-02-25
申请号：US16979933
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Sergio Quezada
IPC: C07K16/28 , A61P35/00 , A61K39/395 , A61K45/06
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in 5 pharmaceutical compositions and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US20210047420A1
公开(公告)日：2021-02-18
申请号：US16979931
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Sergio Quezada
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61P35/00
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US20210009704A1
公开(公告)日：2021-01-14
申请号：US16979935
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , James Geoghegan , Bianka Prinz , Sergio Quezada
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61P35/00
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US11802160B2
公开(公告)日：2023-10-31
申请号：US16782440
申请日：2020-02-05
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , Sergio Quezada , James Geoghegan , Bianka Prinz
CPC classification number: C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/55 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
-
Patent Agency Ranking
公开(公告)号：US20230265200A1
公开(公告)日：2023-08-24
申请号：US17706028
申请日：2022-03-28
Applicant: Cancer Research Technology Limited
Inventor： Sergio Quezada , Karl Peggs , Frederick Arce Vargas
CPC classification number: C07K16/2866 , C07K16/2815 , C07K16/2812 , A61P35/00 , C07K16/2818 , C07K16/2827 , A61K2039/505
Abstract: The present disclosure relates to a method of treating a solid tumour, wherein said method involves the use of an antibody to CD25. In particular, the antibody to CD25 is optimized for depletion of regulatory T cells (Treg) within tumours. The present invention also provides novel anti-CD25 antibodies and their combination with other anti-cancer drugs, such as immune checkpoint inhibitors, compounds that target cancer antigens or the inhibitory Fc receptor FcyRllb (CD32b).
-
公开(公告)号：US20210040221A1
公开(公告)日：2021-02-11
申请号：US16979932
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Sergio Quezada
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions N thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US10745485B2
公开(公告)日：2020-08-18
申请号：US16352717
申请日：2019-03-13
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , Sergio Quezada , James Geoghegan , Bianka Prinz
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US20200000904A1
公开(公告)日：2020-01-02
申请号：US16565350
申请日：2019-09-09
Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
Inventor： Nicholas McGranahan , Rachel Rosenthal , Charles Swanton , Karl Peggs , Sergio Quezada
IPC: A61K39/00 , C12Q1/6886 , C12N5/0783 , G01N33/50 , G01N33/574
Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.
-
公开(公告)号：US20200000903A1
公开(公告)日：2020-01-02
申请号：US16565342
申请日：2019-09-09
Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
Inventor： Nicholas McGranahan , Rachel Rosenthal , Charles Swanton , Karl Peggs , Sergio Quezada
IPC: A61K39/00 , C12Q1/6886 , C12N5/0783 , G01N33/50 , G01N33/574
Abstract: The present invention relates to a method for identifying a truncal neo-antigen in a tumour from a subject which comprises the steps of: i) determining mutations present in a sample isolated from the tumour; and ii) identifying a truncal mutation which is a mutation present in essentially all tumour cells; and iii) identifying a truncal neo-antigen, which is an antigen encoded by a sequence which comprises the truncal mutation.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.022 seconds)
